Alembic Pharmaceuticals Limited

BSE:533573 Stock Report

Market Cap: ₹206.3b

Alembic Pharmaceuticals Valuation

Is 533573 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 533573 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 533573 (₹1048.05) is trading above our estimate of fair value (₹543.75)

Significantly Below Fair Value: 533573 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 533573?

Key metric: As 533573 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 533573. This is calculated by dividing 533573's market cap by their current earnings.
What is 533573's PE Ratio?
PE Ratio31.9x
Earnings₹6.47b
Market Cap₹206.27b

Price to Earnings Ratio vs Peers

How does 533573's PE Ratio compare to its peers?

The above table shows the PE ratio for 533573 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average43.5x
524742 Caplin Point Laboratories
40x13.6%₹197.4b
CONCORDBIO Concord Biotech
69.1x26.9%₹226.5b
530019 Jubilant Pharmova
28.8x5.5%₹171.1b
PFIZER Pfizer
36.1x12.9%₹223.0b
533573 Alembic Pharmaceuticals
31.9x21.5%₹206.3b

Price-To-Earnings vs Peers: 533573 is good value based on its Price-To-Earnings Ratio (31.9x) compared to the peer average (43.5x).

Price to Earnings Ratio vs Industry

How does 533573's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
INDSWFTLAB Ind-Swift Laboratories
1.7xn/aUS$72.21m
524652 Ind-Swift
2.8xn/aUS$18.06m
No more companies available in this PE range
533573 31.9xIndustry Avg. 35.3xNo. of Companies19PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 533573 is good value based on its Price-To-Earnings Ratio (31.9x) compared to the Indian Pharmaceuticals industry average (35.3x).

Price to Earnings Ratio vs Fair Ratio

What is 533573's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

533573 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio31.9x
Fair PE Ratio42.1x

Price-To-Earnings vs Fair Ratio: 533573 is good value based on its Price-To-Earnings Ratio (31.9x) compared to the estimated Fair Price-To-Earnings Ratio (42.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 533573 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₹1,048.05
₹1,161.92
+10.9%
12.6%₹1,412.00₹895.00n/a12
Dec ’25₹1,089.20
₹1,161.92
+6.7%
12.6%₹1,412.00₹895.00n/a12
Nov ’25₹1,121.40
₹1,092.58
-2.6%
13.0%₹1,396.00₹837.00n/a12
Oct ’25₹1,190.45
₹1,092.17
-8.3%
13.0%₹1,396.00₹837.00n/a12
Sep ’25₹1,060.25
₹1,056.33
-0.4%
14.3%₹1,396.00₹837.00n/a12
Aug ’25₹1,215.60
₹985.08
-19.0%
9.9%₹1,229.00₹845.00n/a13
Jul ’25₹923.90
₹983.54
+6.5%
9.8%₹1,229.00₹845.00n/a13
Jun ’25₹923.00
₹980.31
+6.2%
10.1%₹1,229.00₹845.00n/a13
May ’25₹996.75
₹937.69
-5.9%
9.7%₹1,143.00₹770.00n/a13
Apr ’25₹1,004.85
₹901.08
-10.3%
7.3%₹1,023.00₹770.00n/a13
Mar ’25₹1,051.05
₹888.14
-15.5%
8.9%₹1,023.00₹720.00n/a14
Feb ’25₹956.40
₹769.67
-19.5%
13.0%₹915.00₹515.00n/a15
Jan ’25₹765.40
₹742.44
-3.0%
15.2%₹915.00₹515.00n/a16
Dec ’24₹751.10
₹742.44
-1.2%
15.2%₹915.00₹515.00₹1,089.2016
Nov ’24₹712.20
₹723.07
+1.5%
15.1%₹895.00₹515.00₹1,121.4015
Oct ’24₹783.90
₹715.33
-8.7%
14.9%₹895.00₹515.00₹1,190.4515
Sep ’24₹770.00
₹715.33
-7.1%
14.9%₹895.00₹515.00₹1,060.2515
Aug ’24₹775.20
₹598.20
-22.8%
9.0%₹704.00₹515.00₹1,215.6015
Jul ’24₹636.20
₹590.87
-7.1%
8.7%₹704.00₹515.00₹923.9015
Jun ’24₹548.05
₹586.94
+7.1%
8.7%₹704.00₹515.00₹923.0016
May ’24₹556.80
₹601.25
+8.0%
7.7%₹704.00₹540.00₹996.7516
Apr ’24₹495.95
₹603.44
+21.7%
7.3%₹704.00₹540.00₹1,004.8516
Mar ’24₹507.45
₹630.24
+24.2%
14.5%₹944.00₹550.00₹1,051.0517
Feb ’24₹540.00
₹674.63
+24.9%
14.1%₹944.00₹563.00₹956.4016
Jan ’24₹573.05
₹676.50
+18.1%
14.2%₹944.00₹563.00₹765.4016
Dec ’23₹593.65
₹682.75
+15.0%
13.4%₹944.00₹563.00₹751.1016

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/29 02:44
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Alembic Pharmaceuticals Limited is covered by 25 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sarabjit NangraAngel Broking Private Limited
null nullAntique Stockbroking Ltd.
Harith AhamedAvendus Spark